Cambridge Cognition excellent order book, healthy pipeline and further opportunity (VIDEO)

Cambridge Cognition (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss Interim results to 30 June.

Matthew talks us through the highlights for the first half, explains what has been driving growth over the period, the new appointments to the team, developing opportunities in new therapeutic areas such as PTSD and what we can expect from the company over the next 12 months.

Cambridge Cognition Holdings plc (LON:COG) is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition.

You might also enjoy reading  Cambridge Cognition wins £2.2 million neurodegenerative disease trial
Find more news, interviews, share price & company profile here for:
Cambridge Cognition Holdings plc

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp